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Caveat Emptor: The Perils of Panel
Testing in Hereditary Breast Cancer
TO THE EDITOR:
In a recent issue of Journal of Clinical Oncology,
Beitsch et al1 argue for expanded panel testing in all
patients with a diagnosis of breast cancer. Their ar-
gument rests on the ﬁnding that of patients who met
National Comprehensive Cancer Network guidelines,
9.39% had a pathogenic/likely pathogenic (P/LP)
variant, whereas of those patients who did not meet
National Comprehensive Cancer Network guidelines,
7.9% had a P/LP variant. These ﬁgures, however,
include many variants in genes that have no deﬁnite
proven association with an increased risk of breast
cancer.2 These results may thus represent incidental
ﬁndings that could equally be found in an unselected
population and will not inform the management of
their disease. Indeed, even at below the expected
carrier frequency of one in 50, monoallelic variants in
the recessively inherited gene MUTYH account for
a full 20% of the reported ﬁndings in patients who did
not meet NCCN guidelines. These ﬁndings are not
pertinent and amount to population screening.
Reanalysis of the data including only variants in
genes with deﬁnitive evidence for breast cancer
susceptibility3 determines that of patients who met
NCCN guidelines, 6.47% had a P/LP variant, whereas
of those patients who did not meet guidelines, 3.75%
had a P/LP variant (Fig 1). Not surprisingly, as NCCN
guidelines are intended to identify patients who are at
high risk, the majority of variants identiﬁed in patients
who did not meet NCCN guidelines were in the
moderate-risk genes ATM, BARD1, and CHEK2,
which do not affect surgical management. Even the
inclusion of BARD1 as a proven breast cancer gene is
debatable as it is not signiﬁcantly overrepresented in
cases versus controls,4 and a signiﬁcant increase in
breast cancer risk has not been demonstrated.5
Testing using NCCN guidelines missed four P/LP
variants in high-risk genes, three in BRCA2, and one
in PALB2. This represents 0.4% of the tested
population.
The cost of indiscriminate expanded panel testing,
aside from the ﬁnancial implications, lies in the return
of variants of uncertain signiﬁcance (VUSs) to health
care providers with limited understanding of their
meaning. In the study by Beitsch et al,1 the 54% of
patients who were found to have VUSs is un-
acceptably high. These results take time to interpret
and explain to patients and may require follow up,
additional testing, or review in case of reclassi-
ﬁcation.6 Of even greater concern, results are fre-
quently misinterpreted, leading to inappropriate
clinical management. Kurian et al7 found that many
surgeons managed patients with BRCA1/BRCA2
VUSs in the same manner as patients with BRCA1/
BRCA2 pathogenic mutations, and one half of
average-risk patients with VUSs underwent bilateral
mastectomy, which suggests a limited understanding
of results among both surgeons and patients. The
recognized shortage of genetic health professionals8
means that there is no short-term solution to this issue,
but the VUS rate can be minimized by restricting
testing to genes that are clinically relevant to the
patient’s presenting diagnosis.9 In the longer term,
functional studies of genes and variants, as well
as population-level data with accurate phenotyp-
ing, will improve variant classiﬁcation and reduce
uncertainties.6
Lastly, we note that at least one third of the 27 authors
of the work by Beitsch et al1 are employees of or
receive honoraria, research funding, or indirect
support from diagnostic laboratories that are heavily
involved in marketing gene panels, which could result
in a signiﬁcant conﬂict of interest when interpreting of
the results of the study.
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FIG 1. Selected data from Beitsch et al,1 including only genes with
deﬁnitive evidence for breast cancer susceptibility. NCCN, National
Comprehensive Cancer Network.
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